Results 21 to 30 of about 204,259 (398)
Australian Prescriber, 2016 The recent Letter to the Editor about warfarin and beetroot by Louise Vanpraag and the response from Philip Tideman and colleagues1 both miss the point about warfarin and beetroot. It is commonplace for those eating beetroot to have red urine (beeturia) or red faeces, or both, and such symptoms in those taking warfarin can be worrying.
John Raven +4 more
openaire +3 more sources
A framework model for a contextualized and integrated warfarin therapy case in a master of pharmacy program [PDF]
, 2019 © Copyright 2019 American Journal of Pharmaceutical Education.Objective. To develop and integrate a case study on warfarin into a clinical pharmacy workshop. Methods. A framework model was designed and used to create a case study on warfarin therapy. The
Birdi, Amandeep +2 more
core +1 more source
An Atypical Case of Warfarin-Induced Skin Necrosis
Clinical Practice and Cases in Emergency Medicine, 2017 Skin necrosis is a relatively rare, potentially fatal side effect of warfarin. It is most commonly reported within 10 days of initiation of therapy in warfarin-naïve patients.
Lindsay R. Sklar, Anne Messman
doaj +1 more source
Indonesian Journal of Pharmacy, 2020 Warfarin is an oral anticoagulant most-commonly prescribed for prevention and treatment of thromboembolism. It is widely acknowledged that warfarin has both narrow therapeutic index and various drug-food interactions, thus carrying the risk of ...
Vitarani D.A Ningrum +4 more
doaj +1 more source
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]
, 2015 Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core +1 more source
The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study. [PDF]
PLoS ONE, 2016 Warfarin oral anticoagulant therapy (OAT) requires regular and frequent drug adjustment monitored by INR. Interindividual variability, drug and diet interferences, and genetics (VKORC1 and CYP2C9) make the maintenance/reaching of stable INR a not so easy
Donato Gemmati +11 more
doaj +1 more source
Atrial amyloidosis: mechanisms and clinical manifestations
European Journal of Heart Failure, Volume 24, Issue 11, Page 2019-2028, November 2022., 2022 Atrial amyloidosis: pathophysiology and clinical manifestations. Atrial amyloidosis can manifest as part of a systemic disorder (as in amyloid light‐chain [AL] or transthyretin [ATTR] amyloidosis), or be isolated (in the form due to atrial natriuretic type [ANP] accumulation); this last form is often associated with permanent or persistent atrial ...
Giuseppe Vergaro +11 more
wiley +1 more source
ELECTROPHORESIS, Volume 43, Issue 23-24, Page 2302-2323, December 2022., 2022 Abstract Biomolecules such as serum proteins can interact with drugs in the body and influence their pharmaceutical effects. Specific and precise methods that analyze these interactions are critical for drug development or monitoring and for diagnostic purposes.
Sadia Sharmeen +3 more
wiley +1 more source
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]
, 2020 OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD +12 more
core +1 more source
Apixaban versus warfarin in patients with atrial fibrillation.
New England Journal of Medicine, 2011 BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a ...
Christopher B Granger +31 more
semanticscholar +1 more source